This is only a cross-sectional study, but it takes us to an interesting world of glucose metabolism.The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson's disease
AffiliationsDOI: 10.1038/s41598-025-02672-x
- PMID: 40481012
Abstract
This study aimed to evaluate the diagnostic potential of combining 18F-FDG PET and susceptibility-weighted imaging (SWI) to assess cerebral glucose metabolism and iron deposition patterns in Parkinson's disease (PD), and to determine their correlations with clinical progression and diagnostic accuracy. Forty-nine PD patients and 70 age-/sex-matched healthy controls underwent standardized 18F-FDG PET and SWI. Metabolic activity (SUVR) and SWI phase values were quantified in cortical/subcortical regions. Statistical analyses included Mann-Whitney U tests, Pearson/Spearman correlations, and ROC curve analysis to evaluate biomarker-clinical relationships and diagnostic performance. PD patients exhibited hypometabolism in frontal, parietal, and temporal cortices (P < 0.05) and hypermetabolism in the putamen, globus pallidus, and cerebellum (P < 0.05). Cortical hypometabolism correlated with Hoehn-Yahr (H-Y) stages (e.g., temporal lobe: r = - 0.405, P = 0.004) and UPDRS III scores (e.g., frontal cortex: r = - 0.364, P = 0.011). SWI revealed reduced phase values in the substantia nigra, red nucleus, and basal ganglia (P < 0.001), with substantia nigra phase values strongly correlating with H-Y stages (r = - 0.525) and UPDRS III scores (r = - 0.446). Multimodal integration of 18F-FDG PET and SWI achieved superior diagnostic accuracy (AUC = 0.844) compared to single-modality models (PET: AUC = 0.777; SWI: AUC = 0.780, P < 0.0001). The integration of 18F-FDG PET and SWI enhances PD diagnosis by capturing complementary metabolic and iron deposition biomarkers. Cortical hypometabolism may precede subcortical iron accumulation, aligning with Braak staging theory. Limitations include cross-sectional design and technical constraints in SWI quantification. Future studies should validate these findings with longitudinal cohorts and advanced techniques like QSM.
- Forums
- ASX - By Stock
- ATH
- Glucose metabolism and iron accumulation in PD
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
1.1¢

Glucose metabolism and iron accumulation in PD
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
1.0¢ | 1.1¢ | 1.0¢ | $60.81K | 5.737M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 16255465 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 1643984 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
32 | 9305965 | 0.010 |
30 | 26756594 | 0.009 |
15 | 25470226 | 0.008 |
12 | 23772392 | 0.007 |
15 | 24953518 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 1643984 | 2 |
0.012 | 20418298 | 32 |
0.013 | 7744325 | 14 |
0.014 | 13188180 | 7 |
0.015 | 2059976 | 9 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |